DK2262506T3 - Meget flokkulerede triamcinolonacetonid-suspensioner med lav viskositet til intravitreal injektion - Google Patents

Meget flokkulerede triamcinolonacetonid-suspensioner med lav viskositet til intravitreal injektion

Info

Publication number
DK2262506T3
DK2262506T3 DK09720520.7T DK09720520T DK2262506T3 DK 2262506 T3 DK2262506 T3 DK 2262506T3 DK 09720520 T DK09720520 T DK 09720520T DK 2262506 T3 DK2262506 T3 DK 2262506T3
Authority
DK
Denmark
Prior art keywords
triamcinolonacetonide
suspensions
low viscosity
intravitreal injection
highly flocculated
Prior art date
Application number
DK09720520.7T
Other languages
English (en)
Inventor
Bhagwati P Kabra
Ruma Sarkar
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Application granted granted Critical
Publication of DK2262506T3 publication Critical patent/DK2262506T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK09720520.7T 2008-03-11 2009-03-10 Meget flokkulerede triamcinolonacetonid-suspensioner med lav viskositet til intravitreal injektion DK2262506T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3545908P 2008-03-11 2008-03-11
PCT/US2009/036652 WO2009114521A1 (en) 2008-03-11 2009-03-10 Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection

Publications (1)

Publication Number Publication Date
DK2262506T3 true DK2262506T3 (da) 2014-06-10

Family

ID=40548758

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09720520.7T DK2262506T3 (da) 2008-03-11 2009-03-10 Meget flokkulerede triamcinolonacetonid-suspensioner med lav viskositet til intravitreal injektion

Country Status (21)

Country Link
US (3) US8128960B2 (da)
EP (1) EP2262506B1 (da)
JP (1) JP5581227B2 (da)
KR (1) KR101555293B1 (da)
CN (1) CN101959519B (da)
AR (1) AR070824A1 (da)
AU (1) AU2009223649B2 (da)
BR (1) BRPI0909630B8 (da)
CA (1) CA2717605C (da)
CL (1) CL2009000573A1 (da)
DK (1) DK2262506T3 (da)
ES (1) ES2471122T3 (da)
MX (1) MX2010009974A (da)
PL (1) PL2262506T3 (da)
PT (1) PT2262506E (da)
RU (1) RU2481842C2 (da)
SI (1) SI2262506T1 (da)
TW (1) TWI468165B (da)
UY (1) UY31699A1 (da)
WO (1) WO2009114521A1 (da)
ZA (1) ZA201005839B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
EP2262506B1 (en) * 2008-03-11 2014-05-07 Alcon Research, Ltd. Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
AU2009330517A1 (en) * 2008-12-22 2010-07-01 Alcon Research, Ltd. Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye
US20120271272A1 (en) 2010-10-15 2012-10-25 Iscience Interventional Corporation Device for ocular access
CN102008488B (zh) * 2010-11-24 2012-10-10 广州固志医药科技有限公司 一种曲安奈德眼用制剂及其制备方法
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
EP2916827B1 (en) * 2012-11-08 2020-06-10 Clearside Biomedical Inc. Methods for the treatment of ocular disease in human subjects
SG10201702674PA (en) 2013-05-03 2017-06-29 Clearside Biomedical Inc Apparatus and methods for ocular injection
EP3003454B1 (en) 2013-06-03 2020-01-08 Clearside Biomedical, Inc. Apparatus for drug delivery using multiple reservoirs
RU2710491C2 (ru) 2014-06-20 2019-12-26 Клиасайд Байомедикал, Инк. Устройство для инъекции лекарственного средства в глазную ткань и способ инъекции лекарственного средства в глазную ткань
US9694145B1 (en) 2016-03-29 2017-07-04 Joseph Onorato Auto-injector systems and method for delivering cyst medication on demand
CA3062845A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
EP3496680B1 (en) 2016-08-12 2024-10-02 Clearside Biomedical, Inc. Device for adjusting the insertion depth of a needle for medicament delivery
WO2018204515A1 (en) 2017-05-02 2018-11-08 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
WO2019136512A1 (en) * 2018-01-10 2019-07-18 Eye Co Pty Ltd Medical device and pharmaceutical composition for treatment of an eye disease or condition
USD893715S1 (en) 2018-11-06 2020-08-18 Joseph Onorato Measurement guide for a cyst, lesion or skin disorder
WO2020214799A1 (en) * 2019-04-16 2020-10-22 Clearside Biomedical, Inc. Injectable triamcinolone formulations
US10814001B1 (en) 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
CN114010593A (zh) * 2021-11-23 2022-02-08 莱默(北京)药业科技有限公司 一种曲安奈德混悬注射液及制备方法
CN115969784B (zh) * 2022-12-26 2025-10-21 昆明积大制药股份有限公司 曲安奈德注射液的制备方法
WO2025114562A1 (en) * 2023-11-30 2025-06-05 Institut National de la Santé et de la Recherche Médicale Intravitreal spironolactone suspension

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962430A (en) * 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
US4370325A (en) * 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4432964A (en) * 1981-08-24 1984-02-21 Alza Corporation Topical composition containing steroid in two forms released independently from polymeric carrier
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
WO1995003807A1 (en) 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
WO1996020712A1 (en) 1994-12-30 1996-07-11 American Home Products Corporation Clear non-alcoholic hydrocortisone solutions
CA2336703A1 (en) 1998-07-10 2000-01-20 The University Of Sydney Prophylactic treatments of neovascularisation in macular degeneration
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
AUPQ496500A0 (en) 2000-01-06 2000-02-03 University Of Sydney, The Kit
US6395294B1 (en) 2000-01-13 2002-05-28 Gholam A. Peyman Method of visualization of the vitreous during vitrectomy
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
ES2396598T3 (es) * 2000-08-25 2013-02-22 Senju Pharmaceutical Co., Ltd. Preparaciones en forma de suspensiones acuosas
EP1414466B1 (en) * 2001-07-09 2009-08-19 CombinatoRx, Incorporated Combinations for the treatment of inflammatory disorders
US20030129242A1 (en) 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
CA2516782A1 (en) 2003-02-20 2004-09-02 Alcon, Inc. Use of steroids to treat ocular disorders
US20040186084A1 (en) 2003-03-21 2004-09-23 Akorn, Inc. Triamcinolone formulations and methods for their preparation and use
CA2539023A1 (en) * 2003-09-23 2005-04-14 Alcon Inc. Triamcinolone acetonide and anecortave acetate formulations for injection
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20060141049A1 (en) 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
JP2007516297A (ja) * 2003-12-23 2007-06-21 アルザ・コーポレーシヨン 制御送達用薬剤組成物の溶解度を高くする方法および投薬形態物
EP1706095B1 (en) 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
WO2005115411A1 (ja) 2004-05-31 2005-12-08 Senju Pharmaceutical Co, .Ltd. 透明組織可視化剤
US8246949B2 (en) 2004-10-27 2012-08-21 Aciont, Inc. Methods and devices for sustained in-vivo release of an active agent
EP1827378A2 (en) 2004-11-17 2007-09-05 Government of The United States of America, as represented by Secretary, Department of Health and Human Services Steroid formulation and methods of treatment using same
EP1867334A4 (en) * 2005-02-18 2009-07-15 Santen Pharmaceutical Co Ltd METHOD FOR RELIEVING OR AVOIDING A SECONDARY EFFECT OF A STEROID COMPOUND
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
ITRM20050547A1 (it) 2005-11-04 2007-05-05 Sooft Italia S R L Gel oftalmico composto da triamcinolone acetonide e da un polimero poliacrilico.
EP2262506B1 (en) * 2008-03-11 2014-05-07 Alcon Research, Ltd. Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection

Also Published As

Publication number Publication date
UY31699A1 (es) 2009-05-29
US8128960B2 (en) 2012-03-06
TWI468165B (zh) 2015-01-11
AU2009223649B2 (en) 2013-08-29
HK1146464A1 (en) 2011-06-10
RU2010141542A (ru) 2012-04-20
US20090233890A1 (en) 2009-09-17
EP2262506B1 (en) 2014-05-07
JP2011513492A (ja) 2011-04-28
CA2717605A1 (en) 2009-09-17
AU2009223649A1 (en) 2009-09-17
PT2262506E (pt) 2014-06-24
CA2717605C (en) 2012-05-15
US8211880B2 (en) 2012-07-03
ES2471122T3 (es) 2014-06-25
BRPI0909630B1 (pt) 2019-03-26
KR101555293B1 (ko) 2015-10-06
CN101959519B (zh) 2013-03-20
TW200940071A (en) 2009-10-01
SI2262506T1 (sl) 2014-07-31
RU2481842C2 (ru) 2013-05-20
KR20100127267A (ko) 2010-12-03
AR070824A1 (es) 2010-05-05
WO2009114521A1 (en) 2009-09-17
PL2262506T3 (pl) 2014-09-30
JP5581227B2 (ja) 2014-08-27
US20120116216A1 (en) 2012-05-10
BRPI0909630A2 (pt) 2015-09-22
ZA201005839B (en) 2011-10-26
BRPI0909630B8 (pt) 2021-05-25
CN101959519A (zh) 2011-01-26
US20120115829A1 (en) 2012-05-10
MX2010009974A (es) 2010-09-30
EP2262506A1 (en) 2010-12-22
CL2009000573A1 (es) 2010-01-04

Similar Documents

Publication Publication Date Title
DK2262506T3 (da) Meget flokkulerede triamcinolonacetonid-suspensioner med lav viskositet til intravitreal injektion
DK2080901T3 (da) Vindmølle-vindmålings-kompensation
DK2245130T3 (da) Ts23 -alpha-amylasevarianter med ændrede egenskaber
BRPI0910515A2 (pt) composição líquida
BRPI0919158A2 (pt) autorização de operações de servidor
EP3988147C0 (en) INSERT SET
IL212175B (en) Muc1* antibodies
DK2334785T4 (da) Sammensætninger med trombocytindhold
DK2318390T3 (da) Pyrrolforbindelser
BRPI0918823A2 (pt) beta-glicosidases modificadas com estabilidades aperfeicoada
BRPI0906705A2 (pt) Composto heterocíclicos
EP2326553A4 (en) TRIM FLAP
EP2277678A4 (en) Exterior component
EP2236266A4 (en) Injector
IT1392670B1 (it) Iniettore
DK2370778T3 (da) Køretøjsstabilisering
HRP20150932T1 (xx) Heterocikliäśki spojevi
FI20085672A0 (fi) Säiliö
DE112008004073T8 (de) Tank
NO20081295L (no) Dempeanordning
DE602008004642D1 (de) Flüssigkeitseinspritzanordnung
DE112009000350A5 (de) Einspritzvorrichtung
DE502007002482D1 (de) Injektor
BRPI0907519A2 (pt) Antagonistas farmacoforos-pde4-muscarínicos duais
FI20085699A0 (fi) Elektro-optinen komponentti